# Workshop report Guidelines and their valid indicators



8/Feb/2020 Martina Teichert Kenji Fujita

Hotel Zuiderduin Egmond aan Zee, The Netherlands **6-8 February 2020** 

A Working Symposium of the Pharmaceutical Care Network Europe **Right questions, valid answers** 



# What did we learn?

✓The concept of measuring quality of care

✓Major issues to develop indicators for pharmaceutical care

# What did we do?

✓Compare indicator availability and use across countries

✓ Develop a syntax for indicator definitions


✓Translate guideline recommendations into indicators

✓ Develop indicators for Pharm care in diabetes









# What did we learn?

✓The concept of measuring quality of care

✓Major issues to develop indicators for pharmaceutical care

# What did we do?

✓Compare indicator availability and use across countries

✓ Develop a syntax for indicator definitions

✓Translate guideline recommendations into indicators

✓ Develop indicators for Pharm care in diabetes







#### Deliverable 2 A set of indicators for Pharm care in diabetes

Does the have acces labordingny	oharmacist s to relevant results?	Does the pharmacust have access to labresults?	
Pahiant Khawledge - distase - twopy - theopy goals	Does the pharm access to ICP	a cist have C codes/inclication?	ls there a system for phar macists to retei eve lab results?
type 2 + insulin use ∌ metformin.	- The => e - Training for p - Malerial for - Koom for Cou	патаазю Соинисту	PROM: hospital admissions as a nesult of hypoglyciemia
Country	Did I Num that are equipped actual and c		Percentage 21 patients with amputations





Kenji: <u>kfuj2522@uni.sydney.edu.au</u> Martina: <u>m.teichert@lumc.nl</u>



